DCF Tool

ALGN

Align Technology, Inc. – Surgical Appliance and Supplies Manufacturing
align technology is a global medical device company with industry-leading innovative products -- invisalign clear aligners and itero intraoral scanners -- that help dental professionals achieve the clinical results they expect and deliver effective, cutting-edge dental options to their patients. invisalign system invisalign clear aligners have been used to straighten teeth and treat minor to complex malocclusion for more than 3 million patients worldwide. the invisalign system is a combination of proprietary virtual modeling software and rapid mass-manufacturing processes used to develop a treatment plan and with custom-made aligners for each patient. invisalign is prescribed to patients through invisalign-trained orthodontists and general practitioner dentists (gp) and is offered in over 90 countries. learn more at www.invisalign.com itero intraoral scanner the itero scanner’s parallel confocal imaging technology uses optical and laser scanning to achieve a high level of precisi
Analysis Results
Intrinsic Value $67.17
Latest Price $298.02
Relative Value 344% overvalued
Thoughts on this result? Let us know.
Ad
Cash Flow (Millions)
Analysis Parameters
%
%
%
New Ticker
Ad
Analysis Details
Growth Rate Projection

An exponential growth model was fit to the past cash flow data, giving more weight to more recent years. This model determined a growth rate estimate of 15.9%.

Weighted Average Cost of Capital (WACC)

The calculated WACC is 12.3%. This value is used as the default discount rate.

Value of Future Flows

Assuming a growth rate of 15.9%, the cash flows for the next 5 years are projected.

The present value of each year's flow is adjusted to present value using the discount rate.

Year Future flow (million) Present value (million)
2023 377 335
2024 436 346
2025 506 357
2026 587 369
2027 680 381
Terminal Value

Assuming a growth rate after the projection years of 2.0%, the terminal value of the company would be 6730 million. This corresponds to a present value of 3350 million.

Intrinsic Value Per Share

The total present value of the projected cash flows is 1790 million. Adding in the terminal value gives a total present value of 5140 million.

There are presently 76.5 million outstanding shares, so the intrinsic value per share is 67.17.

Financial Statements

The following data was to determine the past cash flows.

Current Assets 2,424,391,000
Current Cash 999,584,000
Current Liabilities 1,925,887,000
Current Debt 0
Non-Cash Working Capital (NCWC) -501,080,000
Change in NCWC 100,258,000
EBIT 654,048,000
Tax Provision 237,484,000
Depreciation and Amortization 125,793,000
Capital Expenditure -291,900,000
Unlevered Free Cash Flow 328,914,933
Current Assets 2,494,075,000
Current Cash 1,171,342,000
Current Liabilities 1,924,071,000
Current Debt 0
Non-Cash Working Capital (NCWC) -601,338,000
Change in NCWC -164,432,000
EBIT 976,400,000
Tax Provision 240,403,000
Depreciation and Amortization 108,729,000
Capital Expenditure -401,098,000
Unlevered Free Cash Flow 287,749,773
Current Assets 1,849,538,000
Current Cash 960,843,000
Current Liabilities 1,325,601,000
Current Debt 0
Non-Cash Working Capital (NCWC) -436,906,000
Change in NCWC -230,728,000
EBIT 387,171,000
Tax Provision -1,396,939,000
Depreciation and Amortization 93,538,000
Capital Expenditure -154,916,000
Unlevered Free Cash Flow 95,065,000
Current Assets 1,633,419,000
Current Cash 868,627,000
Current Liabilities 970,970,000
Current Debt 0
Non-Cash Working Capital (NCWC) -206,178,000
Change in NCWC -81,225,000
EBIT 506,955,000
Tax Provision 112,347,000
Depreciation and Amortization 78,990,000
Capital Expenditure -149,707,000
Unlevered Free Cash Flow 252,414,344
Current Assets 1,302,479,000
Current Cash 735,359,000
Current Liabilities 692,073,000
Current Debt 0
Non-Cash Working Capital (NCWC) -124,953,000
Change in NCWC -62,598,000
EBIT 457,871,000
Tax Provision 57,723,000
Depreciation and Amortization 54,727,000
Capital Expenditure -223,312,000
Unlevered Free Cash Flow 168,975,965
Current Assets 1,157,003,000
Current Cash 721,542,000
Current Liabilities 497,816,000
Current Debt 0
Non-Cash Working Capital (NCWC) -62,355,000
Change in NCWC -20,742,000
EBIT 350,392,000
Tax Provision 130,162,000
Depreciation and Amortization 37,739,000
Capital Expenditure -195,695,000
Unlevered Free Cash Flow 45,559,469
Current Assets 952,978,000
Current Cash 640,256,000
Current Liabilities 354,335,000
Current Debt 0
Non-Cash Working Capital (NCWC) -41,613,000
Change in NCWC 25,344,000
EBIT 247,237,000
Tax Provision 51,200,000
Depreciation and Amortization 24,002,000
Capital Expenditure -70,576,000
Unlevered Free Cash Flow 173,456,230
Current Assets 732,010,000
Current Cash 527,295,000
Current Liabilities 271,672,000
Current Debt 0
Non-Cash Working Capital (NCWC) -66,957,000
Change in NCWC -67,648,000
EBIT 188,634,000
Tax Provision 42,081,000
Depreciation and Amortization 18,004,000
Capital Expenditure -53,451,000
Unlevered Free Cash Flow 42,885,240
Current Assets 657,160,000
Current Cash 454,658,000
Current Liabilities 201,811,000
Current Debt 0
Non-Cash Working Capital (NCWC) 691,000
Change in NCWC 1,346,000
EBIT 193,576,000
Tax Provision 44,537,000
Depreciation and Amortization 17,856,000
Capital Expenditure -24,092,000
Unlevered Free Cash Flow 143,398,719
Current Assets 544,676,000
Current Cash 369,993,000
Current Liabilities 175,338,000
Current Debt 0
Non-Cash Working Capital (NCWC) -655,000
Change in NCWC 4,194,000
EBIT 161,225,000
Tax Provision 28,844,000
Depreciation and Amortization 16,825,000
Capital Expenditure -19,412,000
Unlevered Free Cash Flow 112,902,605
Current Assets 485,793,000
Current Cash 334,871,000
Current Liabilities 155,771,000
Current Debt 0
Non-Cash Working Capital (NCWC) -4,849,000
Change in NCWC 6,522,000
EBIT 122,183,000
Tax Provision 25,605,000
Depreciation and Amortization 17,811,000
Capital Expenditure -38,333,000
Unlevered Free Cash Flow 71,069,783

This analysis is provided for informational purposes only and does not constitute financial or investing advice. For more information on the advantages and limitations of DCF analysis see background. This information is provided on an "as is" basis. No warranty, expressed or implied, is made regarding accuracy, adequacy, completeness, legality, reliability or usefulness of any information. By using this site you agree that under no circumstances shall Valuation Tools LLC be held liable for any loss or damage caused by information obtained from this website including any articles, data, videos, its social media accounts, or any other materials.